Four biologists, a nanoengineer and a biophysicist at UC San Diego today received a total of more than $5 million in grants from the National Institutes of Health to pursue innovative and transformative research projects.
UCTV and the Computer Science and Engineering department have launched The Computer Science Channel” to expand awareness of issues facing computer science and other sectors.
Physician-scientists with Moores Cancer Center at UC San Diego Health have been leading the way in pancreatic cancer care by investigating new therapies as well as offering innovative clinical trials and the latest treatments with a personalized medicine approach. This expertise led to the selection of Moores Cancer Center as one of 12 clinical trial sites for the Pancreatic Cancer Action Network’s newly created Precision Promise, the first large-scale precision medicine trial network designed to transform outcomes for patients with pancreatic cancer.
Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize certain cancer cells to radiation therapy that may improve tumor control and reduce treatment-related side effects.
Researchers at University of California San Diego School of Medicine discovered a pattern of microbes indicative of IBD in dogs. With more than 90 percent accuracy, the team used that information to predict which dogs had IBD. However, they also determined that the gut microbiomes of dogs and humans are not similar enough to use dogs as animal models for humans with this disease. The study is published October 3 in Nature Microbiology.
Approximately 20 percent of all human cancers have mutations in a gene called KRAS. KRAS-mutant cancers are among the most difficult to treat, with poor survival and resistance to chemotherapy. Researchers at University of California San Diego School of Medicine and Moores Cancer Center used microRNAs to systematically inhibit thousands of other genes to find combinations that are specifically lethal to cancer cells driven by a KRAS mutation.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
